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Neuroinflammation and neurodegeneration have been observed in the
brain in type 1 diabetes (T1D). However, little is known about the
mediators of these effects. In T1D mice with 12- and 35-wk duration
of diabetes we examined two mechanisms of neurodegeneration, loss
of the neuroprotective factors insulin-like growth factor I (IGF-I) and
IGF-binding protein-3 (IGFBP-3) and changes in indoleamine 2,3-
dioxygenase (IDO) expression in the brain, and compared the re-
sponse to age-matched controls. Furthermore, levels of matrix metal-
loproteinase-2 (MMP-2), nucleoside triphosphate diphosphohydro-
lase-1 (CD39), and ionized calcium-binding adaptor molecule 1
(Iba-1) were utilized to assess inflammatory changes in astrocytes,
microglia, and blood vessels. In the diabetic hypothalamus (HYPO),
we observed 20% reduction in neuronal soma diameter (P 0.05) and
reduced neuronal expression of IGFBP-3 (32%, P  0.05) and
IGF-I (15%, P 0.05) compared with controls at 35 wk. In diabetic
HYPO, MMP-2 expression was increased in astrocytes (46%, P 
0.01), and IDO cell density rose by (62%, P  0.05). CD39
expression dropped by 30% (P  0.05) in microglia and blood
vessels. With 10 wk of systemic treatment using minocycline, an
anti-inflammatory agent that crosses the blood-brain barrier, MMP-2,
IDO, and CD39 levels normalized (P 0.05). Our results suggest that
increased IDO and early loss of CD39 protective cells lead to activation
of inflammation in sympathetic centers of the CNS. As a downstream
effect, the loss of the neuronal survival factors IGFBP-3 and IGF-I and
the neurotoxic products of the kynurenine pathway contribute to the loss
of neuronal density observed in the HYPO in T1D.
diabetes; inflammation; brain; sympathetic nervous system
IN DIABETES, HYPERGLYCEMIA LEADS TO ACTIVATION of metabolic
signaling pathways such as protein kinase C (PKC), the polyol
pathway, and the advance glycation end products poly(ADP)-
ribose polymerase (PARP) and hexosamine. Activation of
these pathways leads to an increase in oxidative stress that in
turn drives inflammation and cell death (51). This sequence of
changes has been observed not only in target organs of diabetic
microvascular complications such as the retina, kidney, and
nerves but also in the brain, including the hippocampus (43)
and the hypothalamus (HYPO) (38). The hyperosmolality
associated with new-onset type 1 diabetes (T1D) triggers an
increase in neuronal activity and vasopressin production within
the hypothalamus. However, after 6 mo of diabetes, an increase
in the appearance of small hyperchromatic neurons, a decrease
in neuronal density with increases in cleaved caspase-3,
TUNEL staining of neurons, and microglial hypertrophy and
condensation is observed (38).
Neurons, microglia, and astrocytes constitute the major cel-
lular elements in the HYPO, and activation of these cells is
observed along with neuronal degeneration in T1D rats (38,
46). IGF-I and IGF-binding protein-3 (IGFBP-3) comprise
critical components of the IGF system that regulate key aspects
of cell growth, motility, differentiation, and survival in both
normal and pathological conditions. In the central nervous
system (CNS), IGF-I enhances neuronal metabolism (4) and
modulates neuronal excitability (11). IGF-I also has antiapop-
totic (12), antioxidant, and anti-inflammatory roles (28). There-
fore, the IGF system has a key role in protecting neurons
against insults. IGFBP-3 neurons are found in both mouse
and human HYPO (29), and exogenous administration of
IGFBP-3 can protect neurons from apoptosis.
CD39, or nucleoside triphosphate diphosphohydrolase-1, is
a transmembrane protein present on the surface of a variety of
cells, including microglia, vascular endothelial cells, and leu-
kocytes (33, 47). CD39 hydrolyzes adenosine triphosphate
(ATP) and adenosine diphosphate (ADP) to the monophos-
phate form (AMP) (23). Thus ATP-dependent processes are
affected by CD39. Endothelial CD39 plays a critical role in
preventing prothrombotic and proinflammatory effects within
the vasculature and controls leukocyte trafficking between the
blood circulation and tissues (53). CD39 activity can attenuate
microglia phagocytosis (5) and migration (19). Mice deficient
in CD39 are highly susceptible to streptozotocin (STZ)-in-
duced diabetes, with a rapid rate of onset of diabetes and a
100% incidence (13). In contrast, CD39 overexpression has
protective effects against STZ-induced diabetes in mice (14).
Matrix metalloproteinase-2 (MMP-2), one of the many zinc-
dependent endopeptidases, functions primarily to mediate the
degradation or remodeling of the extracellular matrix and has
been implicated in the pathogenesis in diabetes (34). MMP-2
can impact blood-retinal barrier integrity through its disruption
of tight-junction proteins such as occludins (25). Increased
MMP-2 activity facilitates apoptosis of retinal capillary cells
and can contribute to neovascularization associated with end-
stage diabetic retinopathy (39, 40).
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Indoleamine 2,3-dioxygenase (IDO) is the first and rate-
limiting enzyme of tryptophan catabolism through the kynure-
nine pathway (KP) (54). The KP represents the major catabolic
route of tryptophan and is a source of nicotinamide adenine
nucleotide, a cofactor in cellular respiration and energy pro-
duction that plays a central role in DNA repair and transcrip-
tional regulation (1). In addition, IDO plays a key role in
regulation of inflammation. IDO can regulate immune re-
sponses and create immune tolerance, acting as a protective
feedback mechanism against a possible overshooting T cell
response (1). IDO expression is low in normal CNS but
increases greatly during inflammatory conditions (1). Proin-
flammatory cytokines and molecules, especially interferon-,
increase IDO expression (41). With the increases in IDO
expression, the KP downstream products, e.g., quinolinic acid
(QUIN), typically rise and have direct effects on neuronal
toxicity.
The aim of our study was to examine changes in IGF-I and
IGFBP-3 and in IDO expression over time in the brains of T1D
mice. Inflammatory changes were assessed using CD39 and
MMP-2 as markers. In the T1D mice, we also examined the
impact of treatment with minocycline, a tetracycline derivative
that crosses both the blood-brain barrier and has anti-inflam-
matory, antiapoptotic, and antioxidant effects on early inflam-
matory changes in the brain.
MATERIALS AND METHODS
Animals. Male C57/BJ6 mice were obtained from The Jackson
Laboratory (Bar Harbor, ME) and housed in the institutional animal
care facilities at the University of Florida. All animals were treated in
accordance with the Guiding Principles in the Care and Use of
Animals [National Institutes of Health (NIH)] and the Association for
Research in Vision and Ophthalmology Statement for the Use of
Animals in Ophthalmic and Vision Research. All experiments were
approved by the Institutional Animal Care and Use Committee of the
University of Florida.
Experimental diabetes. C57BL/6J mice (The Jackson Laboratory,
Bar Harbor, ME) aged 7–10 wk were rendered diabetic with five
consecutive daily intraperitoneal injections of STZ (55 mg/kg) freshly
dissolved in citrate buffer (pH 4.5). Development of diabetes (defined
by blood glucose 250 mg/dl) was verified 1 wk after the first STZ
injection (Glucometer Elite XL; Bayer, Elkhart, IN). Glycemic control
was estimated on multiple occasions from the measurement of gly-
cohemoglobin (GHb) using either a GHb assay (Glyc-Affin; Perkin-
Elmer, Norton, OH) or a glycohemoglobin assay (Helena Glyco Tek
Laboratory, Beaumont, TX). A minimum of four animals were ex-
amined for each time point. A second group of animals were fed either
minocycline-supplemented chow (1 g/kg) or control chow (Purina
Mills, Gray Summit, MO) beginning at 14 days following the induc-
tion of T1D and then euthanized 10 wk later (12-wk duration of
diabetes mellitus).
Tissue processing. After confirmed diabetes of 12 and 35 wk
duration, T1D animals and age-matched controls were deeply anes-
thetized and perfused intracardially with phosphate-buffered saline
(PBS) followed by 4% paraformaldehyde in 0.1 M phosphate buffer.
Brains were immersion-fixed in 4% paraformaldehyde overnight,
followed by cryoprotection in 20% sucrose-PBS, and mounted in
optimum cutting temperature compound. Serial cross-sections of
brains were cut on a cryostat (20 m thick) and mounted.
Immunofluorescence histochemistry. Sections on slides were
stained with Iba-1 (Wako, Osaka, Japan) for visualization of micro-
glia/macrophages (50), CD39 (AF4398 for mouse retina; R & D
Systems, Minneapolis, MN) for visualization of resident microglia
and blood vessels, ZymedS-100 (18-0046; Zymed, Mulgrave, Vic-
toria, Australia) for astrocyte soma, glial fibrillary acidic protein
antibody (GFAP; GA5) (Sigma, St. Louis, MO) for astrocyte pro-
cesses, MMP-2 (Abcam, MA), IDO (LS-B1746; LSBio), IGF-I (220,
kind gift from Prof. Robert Baxter and Dr. Sue Firth, Kolling Institute,
St. Leonards, New South Wales, Australia), IGFBP-3 (Acris), Neu-
ronal Nuclei (NeuN, MAB 377; Chemicon, Temecula, CA) for neu-
rons, and biotinylated Griffonia simplicifolia (Bandeiraea) isolectin
B4 (GS lectin; Sigma-Aldrich) for endothelial cells and activated
microglia/macrophages. The tissues were washed and transferred to
secondary antibodies conjugated with either Alexa Fluor 594 or Alexa
Fluor 488 (Invitrogen-Molecular Probes, Carlsbad, CA).
Confocal microscopy. Imaging was carried out using a Zeiss LSM
510 Meta confocal microscope at the Bosch Advanced Microscopy
Facility (University of Sydney). Images were captured with the Zeiss
LSM 510 acquisition software (Carl Zeiss). Z-stack images were
collected. The optimal interval, pinhole size, and optical depth pa-
rameters were consistently maintained as required for the 10 	 0.3,
20 	 0.8, 40 	 0.75, 63 	 oil 1.4, and 100 	 oil 1.4 NA objectives
using an image frame size of 1,024 	 1,024 pixels. The laser lines
were 405, 488, 561, and 633 nm. Scan speed and averaging remained
consistent for all image capturing in each experiment for both quali-
tative and quantitative purposes. Image analysis was performed using
LSM 510 Meta 4.2 (Carl Zeiss) offline software and Adobe Photoshop
CS5 version 12.0 software (Adobe Systems, San Jose, CA) on an
Apple Macintosh computer.
Quantitative analysis of Iba-1 microglia and NeuN neuron size.
Confocal images of the HYPO were analyzed to obtain Iba-1
microglia and NeuN neuron soma size (63–100	 images). In each
animal, three images were taken from different sections (random
12–24 cells for each mouse), and the images were analyzed using
ImageJ software (NIH Research Services Branch; http://rsb.info.nih-
.gov/ij/index.html).
Quantitative analysis of Iba-1 microglia/macrophage, CD39
resident microglia, S-100/MMP-2/IDO astrocyte, and NeuN/
IGF-I neuron densities. The densities of Iba-1 microglia/macro-
phage, CD39 resident microglia, MMP-2 astrocytes, and NeuN/
IGF-I neurons were examined in the HYPO. For each region or
tissue, three or more images were taken from different sections for
analysis. The positive cells were determined by their specific antibody
labeling and unique morphology; for example, MMP-2 astrocytes
had star-shaped morphology. The density of positive cells was quan-
tified manually using ImageJ software. S-100 astrocytes were
counted directly under a microscope at 	20 in different focal planes
in the same areas.
Quantitative analysis of CD39, IGF-I, and IGFBP-3 intensity of
immunolabeling. All images in this study were generated using
identical settings for each experiment. For CD39 fluorescence inten-
sity, at least three confocal images (	10) were taken from four or
more samples in each group (12 images in each group). The average
fluorescence intensity in the whole area (including CD39 microglia
and blood vessels) of each image was measured using ImageJ soft-
ware. For IGF-I and IGFBP-3 cell fluorescence intensity, at least
three confocal images (	40–100) were taken from four or more
samples in each group. In each image, 3–4 IGF-I or IGFBP-3 cells
were analyzed using ImageJ software.
Statistical analysis. To account for variation, the density or fluo-
rescence intensity of positive cells was normalized by dividing by the
mean values of age-matched controls in the same region or tissue and
expressed as the percentage of relative densities or fluorescence
intensity for each animal. All data are shown as means 
 SE.
Statistical differences between two groups, for example, control
compared with T1D or T1D compared with T1D with minocycline
treatment, were determined by applying one-tailed Student’s t-tests
for unpaired groups with equal variance. A P value of 0.05 (P 
0.05) was considered to be statistically significant.
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Iba-1 cells show microglial activation in the HYPO of T1D
mice. The hypothalamus of T1D mice (Fig. 1B) with 35 wk of
T1D were examined for Iba-1-labeled microglia. The microglia
showed significantly larger soma diameters and increased var-
icosities in their process fields, with many small Iba-1/GS
lectin granules. These Iba-1 granules often contacted and/or
surrounded DAPI nuclear debris, indicating that Iba-1 mi-
croglia may have been phagocytosing nuclear debris, which is
indicative of microglial activation. Age-matched controls
showed microglia with smaller, round soma with ramified
processes typical of resting microglia (Fig. 1A). Quantitative
analysis also showed that the Iba-1 soma was enlarged (44.42

1.47 vs. 38.04 
 1.14 m2, P  0.05) in diabetic HYPO.
CD39 expression on resident microglia and blood vessels is
reduced in the 12-wk T1D mice and is restored with
minocycline. In control HYPO, CD39 microglia somas and
blood vessels were stained brightly (Fig. 2A); all CD39
microglia were Iba-1, and 99% Iba-1 microglia were
CD39 (Fig. 2B). In contrast in T1D mice with 12-wk diabetes
duration, CD39 expression on microglia and blood vessels was
reduced by 30% (P  0.0019; Fig. 2C compared with control
in Fig. 1A; Fig. 2G shows quantification of fluorescence inten-
sity), whereas the density of CD39 cells decreased only
10% (56.0 
 4.0 in control vs. 50.6 
 1.6/mm2 in diabetic,
P  0.07). Double-labeling indicated that 50% of Iba-1
cells also showed reduced CD39 expression. Approximately
5% of the Iba-1 cells showed no CD39 expression (arrow-
heads in Fig. 2, C and D). These Iba-1/CD39 cells were
always located near blood vessels, suggesting that the cells
entered from the bloodstream and thus were likely bone mar-
row-derived cells.
Previously, we showed that the density of Iba-1 cells in
diabetic HYPO returned toward control levels with 10 wk of
minocycline treatment (30). We extend these studies by examin-
ing the changes in CD39 expression in the minocycline-treated
T1D mice. Fluorescence intensity of CD39 increased 15% in
the HYPO of minocycline-treated T1D mice compared with
diabetic mice without treatment (Fig. 2, E vs. C). Figure 2G shows
the quantitative plots of CD39 expression (control vs. dia-
betic, P  0.0019; control vs. diabetic  minocycline, P 
0.021; diabetic vs. diabetic  minocycline, P  0.028).
Increased S-100 astrocyte density and GFAP expression
in the HYPO and granular insular cortex in 35-wk T1D mice.
The HYPO and granular insular cortex (GIC; Fig. 3, B, D, and
F) are regions modulated by the sympathetic nervous system.
S-100/GFAP astrocytes in these regions of 35-wk T1D
mice became hypertrophic and exhibited bright and thick
GFAP processes compared with controls. These astrocytic
changes occurred in the same regions where microglia activa-
tion was most intense. Quantitative analysis of relative
S-100 cell density (Fig. 3G) shows that diabetic brains had
a higher number of S-100 cells in the HYPO (358.1 
 18.1
cells in diabetic vs. 291.2 
 8.3/mm2 cells in control, P 
0.0049) and GIC (density: 244 
 16.1 cells in diabetic vs.
192 
 20.2 cells/mm2 in control, P  0.0159) compared with
control brains. This latter effect was apparent in regions such
as the HYPO and GIC that are modulated by the sympathetic
nervous system but not in other regions such as the basal
nuclear region (115.2 
 12.3 cells in diabetic vs. 99.8 
 4.3
cells/mm2 in control, P  0.1366).
MMP-2 expression is increased in cells of HYPO of T1D
mice and is reduced with minocycline. MMP-2 can be ex-
pressed by astrocytes and microglia (45) and on blood vessels
following stimulation with inflammatory cytokines (27). Stel-
late MMP-2 astrocytes were observed to be distributed un-
evenly across control mouse brain sections. In the HYPO,
MMP-2 cells were more prominent in the periventricular
region (Fig. 4A), with the density of MMP-2 cells being
91.0 
 6.6/mm2 in control HYPO. Double-labeling with
MMP-2 and GFAP showed that 98% of MMP-2 cells were
GFAP astrocytes (Fig. 3, A and B), which confirmed previous
studies (35). GS isolectin B4 (GS lectin) plus microglia and
blood vessels were MMP-2 negative (data not shown).
In the HYPO of 12-wk diabetic mice, the density of
MMP-2 cells increased to 133.3
 11.4/mm2 (compared with
control, P  0.009; Fig. 4, C and G). Approximately 95%
MMP-2 cells were GFAP positive (Fig. 4, C and D), whereas
5% of MMP-2 cells were GFAP negative (Fig. 4, C and D,
arrows). Minocycline treatment restored the density of
MMP-2 cells to control levels (90.5 
 12.4/mm2; compared
with control, P 0.48; compared with diabetic, P 0.03, Fig.
3, E–G).
Fig. 1. ionized calcium-binding adaptor molecule 1 (Iba-1) microglial activation in the hypothalamus (HYPO) of type 1 diabetic (T1D) mice at 35 wk. A and
B: HYPO region of mouse brain sections triple-stained with Iba-1 (red), GS-lectin (green), and 4,6-diamidino-2-phenylindole (DAPI; blue). A: in controls, Iba-1
microglia had smaller, round somas with long, ramified processes that showed weak GS lectin staining (green). B: in diabetic HYPO, the somas of Iba-1
microglia were larger than that of the controls and showed a marked increase in GS lectin activity. Microglia in diabetic HYPO had short and thicker processes,
and the processes became more complex and armed with numerous small Iba-1/GS lectin spots. These Iba-1 granules often contacted and/or surrounded
DAPI (blue) nuclear debris (arrow), indicating that Iba-1 microglia may phagocytose nuclear debris.
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Increased IDO/GFAP astrocyte density in the HYPO of
T1D mice is mitigated by minocycline. Weak IDO expression
was seen on GFAP astrocytes in control HYPO (Fig. 5, A and
B). In contrast with the HYPO of T1D mice with 12-wk
duration of diabetes (Fig. 5, C and D), IDO/GFAP cells
were increased in number and brightness. Minocycline treat-
ment in diabetic mice (Fig. 5, E and F) returned the density and
brightness of IDO/GFAP astrocytes to control levels. Quan-
titative analysis (Fig. 5G) showed that the IDO cell density
was significantly higher (P 0.05) in diabetic HYPO (176.1

3.4) compared with control (109.0 
 6.9) or T1D mice treated
with minocycline (108.6 
 3.7).
IGF-I immunoreactivity is decreased in NeuN neurons of
35-wk T1D HYPO mice. In controls, IGF-I cells were distrib-
uted evenly throughout the HYPO (Fig. 6A). All IGF-I cells
were NeuN neurons (Fig. 6, A–C). In the 35-wk diabetic
HYPO (Fig. 6, D–F), IGF-I cells showed reduced density
(431.8 
 28.0 in diabetic vs. 504.4 
 7.8/mm2 in control, P 
0.023) and intensity of IGF staining (Fig. 6, A vs. D).
The density of NeuN neurons in the diabetic HYPO was
similar to that of the control group (1,244.1 
 2.2/mm2 in
control and 1,250.7 
 2.8/mm2 in diabetic; Fig. 6, B vs. E).
However, increased numbers of NeuN/IGF-I neurons were
observed in the diabetic HYPO (compare Fig. 6, C and F)
compared with control HYPO. Higher-power confocal images
showed that IGF-I was localized to granules in both the
control (Fig. 6G) and diabetic HYPO (Fig. 6J).
In the 35-wk diabetic HYPO, IGF-I granules in NeuN
neurons and IGF-I immunoreactivity was decreased (Fig. 6,
G–I compared with J–L). The size of NeuN neurons was also
reduced in diabetic HYPO (compare Fig. 6, H and K). Quan-
titative analysis showed that the density of IGF-I cells de-
creased in the HYPO at both 12 (448.0 
 31.6 cells in control
vs. 382.4
 14.5/mm2 in diabetic, P 0.0.048) and 35 wk (see
above) postinduction of diabetes (Fig. 6M). However, mino-
cycline treatment in the T1D mice with 12-wk duration of
diabetes did not increase the IGF-I cell density (409.2 

17.8/mm2, P  0.138 with diabetic; Fig. 6M).
The size of NeuN neurons was 84.8 
 7.1 m2 in control
but was reduced to 69.7 
 6.3 m2 in 35-wk diabetic mice
(P  0.011) (Fig. 6N). Quantitative analysis showed a 15%
loss of IGF-I fluorescence intensity at 35 wk postinduction
(P  0.03) but not at 12 wk postinduction (Fig. 6O).
Reduction of IGFBP-3 fluorescence intensity in neurons in
the HYPO of 35-wk but not 12-wk T1D mice. Cells stained for
the prosurvival factor IGFBP-3 were widely distributed across
the control brain sections, including the HYPO (Fig. 7A), GIC
(images not shown), and basal nucleus (BN) region (Fig. 7C).
In the 35-wk diabetic brain (Fig. 7, B and D), IGFBP-3
immunoreactivity was reduced by more than 32% (P  0.006)
in HYPO (Fig. 7, A vs. B) but not in BN (P  0.477; Fig. 7,
Fig. 2. Iba-1 cell density increased, whereas CD39 fluorescence intensity on
microglia and blood vessels (BV) was reduced in the HYPO in 12-wk T1D
mice. These changes were mitigated by treatment with minocycline. A–F:
HYPO region of mouse brain sections double-stained with CD39 (red) and
Iba-1 (green). A and B: control animals. C and D: diabetic mice at 12 wk
postinduction. E and F: diabetic mice treated with minocycline at 12 wk
postinduction. CD39 staining in each of the respective groups is shown in A,
C, and E, whereas CD39/Iba-1 double labeling is shown in B, D, and F. In
controls (A and B), CD39 was expressed on microglia and BV (A); double-
labeling (B) shows that all CD39 cells in controls were Iba-1 positive (arrows
in A and B indicate a double-labeled cell). At 12 wk postinduction of diabetes
(C and D), CD39 expression on microglia-like cells and BV was reduced in
fluorescence intensity (C); double-labeling (D) shows some Iba-1 cells
without CD39 expression (arrowheads in C and D; arrows in C and D indicate
Iba-1 cells lacking CD39 expression). With minocycline treatment in diabetic
mice (E and F), CD39 expression on microglia-like cells and BV was
recovered (C). F: Iba-1 cells were reduced in density (arrows in E and F
indicate the same cell). G: quantitative analysis shows that the relative
fluorescent intensity of CD39 cells decreased significantly (*P  0.001) in
diabetic brains (black bar) compared with control (open bar). With minocy-
cline treatment, the relative fluorescent intensity of CD39 cells became
significantly higher (†P  0.03) than in diabetic brains (gray bar compared
with black bar) but was still significantly lower than in control brains (gray bar
compared with open bar) (†P  0.03). Calibration in A applies to A–F.
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Fig. 3. Astrocytes were activated in the HYPO and granular insular cortex (GIC)
of 35-wk T1D mice. Antibodies against both GFAP and S-100 were applied to
HYPO and GIC mouse brain sections to visualize astrocytes in control and T1D
mice at 35 wk. Both glial fibrillary acidic protein (GFAP) and S-100 visualize
astrocyte morphology; S-100 predominantly stains astrocyte somas (green),
whereas GFAP visualizes cytoskeletal filament proteins within the cytoplasm
(red). A–D: regions at low magnification, demonstrating a markedly higher density
of astrocytes in T1D at 35 wk in these regions. E and F: HYPO at higher
magnification, confirming that all astrocytes express both GFAP and S-100. G:
relative quantitative analysis of GFAP/S-100 astrocyte cell density in 3
regions of the brain showed that in the 35-wk diabetic HYPO (B and F) and GIC
(D) (central nervous system regions connected with the bone marrow), astrocytes
showed a significantly (*P  0.05) increased density compared with control brains;
however, there was no significant difference evident in the basal nucleus (BN; a region
of the brain that is not connected to the bone marrow). Scale bar in A applies to A–D.
Scale bar in E applies to E and F. V, 3rd ventricle.
Fig. 4. Matrix metalloproteinase-2 (MMP-2)/GFAP cell density was in-
creased in the HYPO in 12-wk T1D mice, and minocycline mitigated MMP-2
expression. A–F: HYPO region of mouse brain sections double-stained with
MMP-2 (green) and GFAP (red). In controls (A and B), almost all MMP-2
cells were GFAP astrocytes. In the 12-wk diabetic HYPO (C and D),
MMP-2 cells increased in number and fluorescent intensity, whereas some
MMP-2 cells were GFAP negative (arrows). With minocycline treatment in
diabetic mice (E and F), the density and fluorescent intensity of MMP-2 cells
returned to control levels. G: relative quantitative analysis shows that the
MMP-2 cell density was higher in diabetic brains (black bar) compared with
controls (open bar; 133.3 
 11.4 vs. 91.0 
 6.6/mm2; *P  0.009) and T1D
with minocycline treatment (gray bar; 133.3 
 11.4 vs. 90.5 
 12.4/mm2;
#P 0.03). There was no significant difference between control and T1D with
minocycline treatment (91.0 
 6.6 vs. 90.5 
 12.4/mm2, P  0.48). Calibra-
tion in A applies to A–F.
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C vs. D). High-resolution confocal images showed that
IGFBP-3 cells contained many IGFBP-3 granules in both
the control (Fig. 6E) and diabetic HYPO (Fig. 7F). These
IGFBP-3 granules were located mostly within NeuN neu-
rons (Fig. 7, E and F). Some IGFBP-3 granules were apparent
in between neurons expressing IGFBP-3, suggesting that the
IGFBP-3 produced in these cells is released into the sur-
rounding extracellular space. There were more IGFBP-3
granules both within the cells and in the extracellular space of
controls (Fig. 7E) than of diabetics (Fig. 7F). The quantitative
data show that IGFBP-3 fluorescence intensity was reduced in
HYPO (see above) and GIC (30%, P  0.032) but not in BN
(see above; Fig. 7G). The decrease in IGFBP-3 immunore-
activity occurred in 35-wk but not 12-wk postinduction (Fig.
7H), and minocycline treatment during the first 3 mo of
diabetes did not change the levels of IGFBP-3, implying that
the loss of IGFBP-3 in neurons is a later event in diabetes.
DISCUSSION
The major findings of this study include that in T1D the
HYPO exhibits 1) a reduction in CD39 expression on resident
microglia and blood vessels; 2) an increase in S-100 astro-
cyte density and GFAP expression, suggesting diabetes in-
duced astrocyte activation; 3) increased MMP-2 and IDO
expression in astrocytes, further supporting astrocyte activa-
tion; and 4) a decrease in IGF-I and IGFBP-3 immunore-
activity in NeuN neurons with fewer IGF-I neurons at 35
wk of T1D; and also 5) that the changes observed in Iba,
S-100, IGF-I, and IGFBP-3 at 35 wk were limited to the
expression of regions associated with sympathetic regulation,
specifically the HYPO and the GIC.
Metabolic pathways associated with the shunting of excess
glucose are known to generate hyperglycemia-induced tissue
damage. The polyol pathway, activated during hyperglycemia,
leads to consumption of NADPH and depletion of glutathione,
which lower the threshold for intracellular oxidative injury.
Increased formation of advanced glycation end products dam-
ages endothelial cells, thus contributing to vascular damage.
Diacylglycerol activation of PKC during hyperglycemia re-
duces blood flow and increases vascular permeability. In-
creased shunting of glucose into the hexosamine pathway leads
to increased proteoglycan and O-linked glycoprotein synthesis.
PARP activation, a downstream effector of oxidant-induced
DNA damage, is an obligatory step in functional and metabolic
changes in the diabetes (52). With time, activation of these
metabolic pathways contributes to the pathogenesis of vascular
and end-organ damage (Fig. 8). Metabolic activity within these
pathways does not depend on neuronal activity and represents
a neurologically “passive” response to high glucose conditions.
A critical question remains. Do neurons serve only as
end-organ targets of the disease process in diabetes, or do they
also actively drive the pathogenesis of end-organ damage?
Previously, we sought to address this question and examined
the infiltration of bone marrow cells into centers modulated by
the sympathetic nervous system, such as the GIC and the
HYPO. We found both an increase in the number of infiltrating
cells and a change in their activation state. Not surprisingly,
this in turn was accompanied by an increase in activation of
resident microglia. Using GFP chimeric mice to track bone
marrow cell extravasation from the circulation into the hypo-
Fig. 5. Indoleamine 2,3-dioxygenase (IDO) expressed in GFAP astrocytes
increased in density in 12-wk diabetic HYPO, and minocycline (MCN)
mitigated IDO expression. A–F: HYPO region of mouse brain sections
double-stained with IDO (green) and GFAP (red). In controls (A and B),
almost all IDO cells were GFAP astrocytes. In the 12-wk diabetic HYPO
(C and D), IDO cells increased in number and brightness. With minocy-
cline treatment in diabetic mice (E and F), the density and brightness of
IDO cells returned to control levels. G: relative quantitative analysis
showed that the density of IDO astrocytes was significantly (P  0.05)
higher in diabetic HYPO (black bar) (176.1 
 3.4) compared with controls
(open bar) (109.0 
 6.9). However, treatment of T1D animals with
minocycline (gray bar) resulted in no statistical difference in IDO expres-
sion observed between control and minocycline-treated T1D animals,
(109.0 
 6.9 vs. 108.6 
 3.7, respectively). Calibration in A applies to
A–F.
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thalamus, we showed that, in diabetic hypothalamus, CD45/
CCR2/GR-1/Iba-1 bone marrow-derived monocytes in-
vaded retina, brain, and kidney (30) and that CCL2 and IL-1
mRNA were significantly increased. These studies are in
agreement with Luo et al. (46), who showed that, in diabetic
hypothalamus, OX42, or CD11b, microglia increase. These
results collectively suggest that the increased microglia/mac-
rophages in diabetic hypothalamus belonged mainly to the M1
microglia/macrophage lineage.
In this study, we sought to further examine possible medi-
ators responsible for this increased extravasation and activa-
tion. The loss of CD39 reactivity selectively seen in the
vasculature of the HYPO and GIC would result in facilitated
adhesion and subsequent extravasation of inflammatory cells
into these specific regions. Critical to extravasation is the
expression of proteases by the migrating leukocytes. The
increase in MMP-2 expression observed could support in-
creased extravasation of monocytes into the CNS. Similarly,
the increase in activation of astrocytes observed in the brains of
the diabetic mice would facilitate blood-brain barrier leakage
and monocyte extravasation.
Hypothalamic inflammation has been observed in obesity
and involves microglia and astrocyte activation and increased
expression of TNF, IL-1, and IL-6 (7, 8, 24). Although
Fig. 6. IGF-I neurons decreased in density and fluores-
cence intensity, and neuronal nuclei (NeuN) neurons were
reduced in size in the 35-wk diabetic HYPO, but IGF-I
expression was only partially affected in 12-wk T1D
HYPO. A–L: HYPO of mouse brain sections double-stained
with IGF-I (red) and NeuN (green). IGF-I cells were
widely distributed in the control HYPO (A). In the diabetic
HYPO (D), IGF-I cells decreased in density and fluores-
cence intensity. All IGF-I cells were also NeuN neurons
in both control (A–C) and diabetic animals (D–F). NeuN
cell densities were similar in control and diabetes (compare
B with E); however, NeuN/IGF-I neurons were increased
in diabetic HYPO compared with control HYPO (compare
C with F, where there is an increase in NeuN/IGF-I cells
in F). In the higher magnification (G–I), IGF-I cells
consisted of IGF-I granules in the control (G) and diabetic
HYPO (J) and a population of IGF-I/NeuN neurons
(G–L). In the diabetic HYPO, NeuN neurons were re-
duced in size (compare H with K; quantitative data in N)
and had fewer IGF-I granules (compare I with L; quanti-
tative data in O). M: relative quantitative analysis shows
that the density of IGF-I neurons decreased in HYPO at
both 12 and 35 wk postinduction. There was no difference
between control and T1D with minocycline treatment at 12
wk postinduction. Actual cell density nos. and P value are
given in the text. N: quantitative analysis of the size of
NeuN neurons in the respective fields of view shows that
their area is reduced from 84.8 
 7.1 m2 in control to
69.7
 6.3 m2 in diabetic mice. O: quantitative analysis of
relative fluorescence intensity shows that the IGF-I immu-
noreactivity decrease was statistically significant within the
positive cells at 35 wk postinduction but not at 12 wk
postinduction. Calibration in A applies to A–F; calibration
in G applies to G–L. *P  0.05.
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hypothalamic inflammation has been less well studied in T1D,
it has been seen in STZ-induced T1D rats and is accompanied
by both microglia and astrocyte activation, and neuronal de-
generation (38, 45, 46).
In our study, all CD39 microglia were Iba-1 positive in
both control and diabetic HYPO (Fig. 2, A–D), suggesting that
these microglia were resident cells and not derived from the
bone marrow. CD39 is expressed only on resident microglia,
and thus CD39 reactivity is able to distinguish resident
microglia from infiltrating bone marrow-derived macrophages
(6). In control HYPO, the CD39 cells had a similar density to
Iba-1 cells (Fig. 2, A and B). In the diabetic HYPO, the
density of CD39 microglia did not change, but their CD39
immunoreactivity was reduced compare (Fig. 2C with Fig. 2A;
quantitative data are shown in Fig. 2, G and F). Some Iba-1
cells were without CD39 labeling (arrows in Fig. 2, C and D),
suggesting that these were derived from the blood (bone
marrow derived) and had extravasated from the circulation. As
expected, these cells were often found alongside the CD39
blood vessels. The increased number of Iba-1/CD39 cells in
the diabetic HYPO suggests that the invading macrophages/
monocytes were bone marrow-derived rather than resident
macrophages, which is consistent with our previous report
(30). This also suggests that bone marrow-derived macro-
phages can be identified by using CD39/Iba-1 double-labeling
and would not require generation of bone marrow chimeras
with GFP, which would facilitate the examination of these cells
and their behavior in human tissues.
Fig. 7. Fluorescence intensity of IGF-binding protein-3 (IGFBP-3) neurons was
decreased in the HYPO of 35 wk T1D; however, this change was not observed at 12
wk. Furthermore, an increase in IGFBP-3 fluorescence intensity was also observed in
the GIC but not in the BN. A and B: HYPO of mouse brain sections single-stained with
IGFBP-3. Compared with control (A), IGFBP-3 neurons decreased in fluorescence
intensity at 35 wk postinduction of diabetes (B). C and D: BN of mouse brain sections
single-stained with IGFBP-3. This pair of images shows that there is no significant
difference in IGFBP-3 neuron fluorescence intensity between control (C) and diabetic
35-wk mice (D) in BN. E and F: HYPO of mouse brain sections double-stained with
IGFBP-3 (red) and NeuN (green). The higher-power images show that NeuN
neurons contained a greater number of IGFBP-3 granules in control (E), and a large
amount of these IGFBP-3 granules were in the interneuronal space. In the 35-wk
postinduction diabetic HYPO (F), both the amount of IGFBP-3 granules within the
neurons and the intercellular space between the cells was reduced (compare E with F).
G: quantitative analysis showed that the IGFBP-3 fluorescence intensity was decreased
at 35 wk (*P 0.05) but not at 12 wk postinduction (data not shown). H: quantitative
analysis showed that decreased IGFBP-3 fluorescence intensity was seen in HYPO and
GIC but not in the BN at 35 wk postinduction. Calibration in B applies to A–D;
calibration in F applies to E and F.
Fig. 8. Interconnections of hypothalamic inflammation in T1D. In T1D,
hyperglycemia-induced biochemical alterations drive oxidative stress and lead
to the activation of microglia and astrocytes, vascular changes, and neuronal
degeneration. In T1D HYPO, most microglia observed displayed an enlarged
soma and a mildly activated morphology (Fig. 1). Iba-1 microglia/macro-
phages increase in density (30), whereas Iba-1/CD39 resident microglia
displayed a reduced CD39 fluorescence intensity compared with controls (see
Fig. 2). CD39 fluorescence intensity on BV was also reduced in T1D (see Fig.
2). S-100/GFAP/MMP2/IDO astrocytes in T1D HYPO increased in
density (see Figs. 3–5). The fluorescence intensity of IGF-I and IGFBP-3 on
neurons decreased (see Figs. 6 and 7), possibly because of an increased
expression of MMP-2 and IDO on astrocytes. In contrast, the fluorescence
intensity of c-fos on neurons increased (30). Activated microglia and astrocytes
in T1D HYPO could produce proinflammatory cytokines, i.e., cysteine chemo-
kine ligand 2 (CCL2) (30). Proinflammatory cytokines, increased IDO, and
loss of IGF-I and IGFBP-3 resulted in neuronal degeneration (Fig. 5N), which
may further contribute to hypothalamic inflammation in T1D. PKC, protein
kinase C; AGE, advanced glycation end product; PARP: poly(ADP-ribose)
polymerase.
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We observed a reduction in CD39 expression in T1D that
would typically result in a decrease in adenosine. Thus, the
beneficial effects of adenosine would be reduced in diabetes.
Adenosine reduces inflammation (21) and prevents the devel-
opment of diabetic retinopathy by augmenting IL-10-induced
STAT3 signaling in M2 macrophages (21, 44). In contrast,
increased extracellular ATP contributes to the progression of
inflammation in diabetic retinas by activation of the P2X7
receptor (56). Thus, when CD39 expression and activity are
reduced, ATP levels will rise and adenosine levels will fall,
promoting inflammation, which supports our hypothesis and
the results.
CD39 activity also attenuates microglia phagocytosis and
migration (5, 19). Endothelial CD39 plays a critical role by
terminating the prothrombotic and proinflammatory effects of
circulating ATP and ADP, thus tightly regulating hemostasis to
prevent excessive clot formation. Blood flow distribution and
oxygen delivery are regulated by circulating ATP released by
erythrocytes (18). Thus, loss of endothelial CD39 could reduce
blood flow and promote hypoxia in the diabetic HYPO.
During acute hypoxia and inflammation associated with
T1D, cellular ATP release may promote excessive inflamma-
tory responses that contribute to altered endothelial barrier
function and promote leukocyte adhesion and transmigration in
affected areas (53, 61). With the loss of CD39, increased ATP
levels can induce cell death (42). Reductions in CD39 expres-
sion on blood vessels in T1D HYPO may allow bone marrow-
derived macrophages to invade more easily. Reducing CD39
expression on resident microglia facilitates activation when
bone marrow-derived monocytes invade.
Expression and activity of MMP-2 are elevated in patients
with T1D (34) and T2D (55). Increased MMP-2 expression in
retina and vitreous (40) is also seen in individuals with diabetic
retinopathy. MMP-2 facilitates the apoptosis of retinal capil-
lary cells via damaging the mitochondria (49). Relevant to this
study is that the enhanced expression of MMP-2 (Fig. 3)
promotes cell death and when expressed by monocytes/mac-
rophages promotes their migration and inflammation and may
cleave IGFBP-3 (22).
IDO can play a role in the regulation of inflammation. In
mammals, IDO (58) is expressed in macrophages, endothelial
cells, neurons, and astrocytes (3). Interferon- (IFN) is an
essential factor for the induction of IDO; however, many other
proinflammatory cytokines such as TNF and IL-1 can also
enhance IDO expression (3, 9). In support of this, we previ-
ously showed increased IFN and IL-1 mRNA in the diabetic
HYPO (30). In the brain, enhanced IDO expression increases
production of neurotoxins such as QUIN and 3-hydroxyan-
thranic acid to lead to neurodegeneration (41).
Microglial activation, invasion of bone marrow-derived
cells, astrocyte activation, and increased MMP-2 expression
occurred only in specific regions such as the HYPO and GIC
but not in the BN of T1D brain. This selective localization of
activated microglia suggests unique features of these regions of
the brain. Our studies would suggest that centers that are
modulated by the sympathetic nervous system may exhibit
more neuronal damage than other regions of the brain in
diabetes due to the selective infiltration of the bone marrow-
derived cells and subsequent activation of resident microglia.
To support this contention, it is known that neurons in the
HYPO change their morphology and molecular expression in
response to chronic stress (26). HYPO neurons in diabetic
animals can undergo degeneration (46), showing distension of
rough endoplasmic reticulum, swollen mitochondria, and en-
hanced electron density of their cytoplasm (17). Neurons in the
diabetic HYPO show increased arginine, oxytocin, N-methyl-
D-aspartate receptor 1, neuronal nitric oxide synthase (NOS),
and vasopressin expression but downregulated expression of
GluR2/3 (20, 46). Both hyperglycemia and hyperosmolality
trigger increased neuronal activity (38). Although we observed
similar neuron numbers in both control and diabetic HYPO
(Fig. 4G), neuron size was reduced (compare Fig. 4, H and K)
in T1D and is consistent with the neuronal shrinkage observed
by Klein et al. (38).
Expression of IGFBP-3 and IGF-I was reduced in the HYPO
neurons (Figs. 6 and 7), whereas c-Fos expression in HYPO
neurons was increased in the diabetic mice (30). IGF-I is
produced by all neurons in the CNS (15), including developing
and adult hypothalamic neurons (16). IGF-I enhances neuron
metabolism (4), modulates neuronal excitability (11), and pro-
tects against apoptosis (12), oxidative stress, and inflammation
(28). Thus, IGF-I is crucial for protecting neurons against
hypoxic-ischemic insults (10). In STZ-induced diabetic rats,
the circulation levels of IGF-I dropped more than fourfold 16
days post-STZ induction compared with controls (1), with
accompaning reductions in brain IGF-I levels (59). Our find-
ings are in agreement with the studies of Aksu et al. (1), as
IGF-I neurons showed decreased density and immunoreac-
tivity in the diabetic HYPO (Fig. 6). Considering the protective
roles of IGF-I, the reduced levels observed in the neurons of
the diabetic HYPO would make these neurons more vulnera-
ble. Similarly, decreased IGFBP-3 immunoreactivity (Fig. 7)
could make neurons more susceptible to damage. Hyperglyce-
mia in STZ-induced diabetes can induce increased basal oxy-
gen consumption, thereby causing hypoxia (2) and promoting
neuronal death (60). Previously, we have demonstrated that
IGFBP-3 can protect cells from apoptosis during hypoxia (36).
IGFBP-3 has vascular effects, including 1) stimulation of
endothelial NOS activity and increasing nitric oxide (NO)
generation via the phosphatidylinositol 3-kinase/Akt signaling
pathway by activation of SR-B1 (32), 2) vasodilatation and
mediation of vascular repair by increasing NO generation (37),
and 3) protection of blood-retinal barrier integrity (32). Thus,
it could be that loss of IGFBP-3 contributes to the neuronal
pathology observed in the HYPO.
Previously, we have shown that minocycline could mitigate
the invasion of CD45/CCR2/GR-1 bone marrow-derived
monocytes in T1D HYPO (30). Minocycline also reduced the
density of Iba-1 microglia/macrophages in both the HYPO
and retina in T1D. In this study, minocycline corrected CD39
expression in microglia and blood vessels toward control
nondiabetic levels. Minocycline reduced GFAP activation in
astrocytes and MMP2 expression (Fig. 4). Minocycline can
reduce microglial-derived membrane type 1 (MT1)-MMP (48).
MT1-MMP is a MMP-2 membrane-bound activator and
cleaves inactive pro-MMP-2 into MMP-2 via activation of
Toll-like receptors and the p38 mitogen-activated protein ki-
nase (MAPK) pathway (48). Minocycline can block p38
MAPK pathway activation in microglia (57) and represents a
therapeutic candidate against inflammation in T1D. The in-
creased expression of Iba-1, MMP-2, and IDO and the reduced
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expression of CD39 in the diabetic HYPO were all mitigated
by treatment with minocycline.
Our studies provide additional insight into the impact of
T1D on the sympathetic centers of the CNS. Infiltration and
activation of bone marrow cells that infiltrate sympathetic
centers and the accompanying activation of resident microglia
are promoted by T1D-induced vascular changes, including loss
of CD39 reactivity that can facilitate adhesion and extravasa-
tion of bone marrow-derived monocytes into these regions.
Critical to their extravasation is the expression of proteases,
including MMP-2. The activation of astrocytes in the brain
further facilitates blood-brain barrier leakage and leukocyte
extravasation. In the brain, enhanced IDO expression increases
production of neurotoxins such as QUIN and 3-hydroxyan-
thranic acid to promote neuronal damage by reducing levels of
neuronal protective factors (41). The changes in the blood-
brain barrier and in microglia and astrocyte activation may
contribute to the loss of the neuronal survival factors IGF-I and
IGFBP-3 that is manifested as neuronal degeneration.
Our study would support that diabetes-induced oxidative
damage in the CNS can lead to activation of microglia with the
subsequent release of inflammatory cytokines. These proin-
flammatory cytokines in turn can activate astrocytes. Activa-
tion of astrocytes results in increased IDO expression, which
increases production of neurotoxins (41). This in turn can
result in reduced expression of the neuronal protective factors
IGF-I and IGFBP-3 (Fig. 8). Use of agents such as minocycline
that cross the blood-brain barrier to reduce neuroinflammation
may provide a useful addition to the armamentarium of agents
used to treat diabetes-induced CNS pathology.
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